Pricing Log in Create free account
Saturday 17 October 2026 Export MRK’s income statement to Excel — free account

Merck & Co., Inc.

MRK Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.

145.95 0.76 +0.52%
Market cap
$358.2B
P/E
117×
Fwd P/E
53.9×
Dividend yield
2.33%
F-score
4/9
Altman Z
3.77
Beneish M
−2.27
Dividend safety
74/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Merck & Co., Inc. (MRK) Shares outstanding

Alert me on Shares outstanding

Merck & Co., Inc.'s shares outstanding at the end of fiscal 2025 was $2.5B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $2.5B. Over the past ten years it has ranged from $2.5B (fiscal 2025) to $2.8B (fiscal 2015) — the current reading is the lowest in ten years. Merck & Co., Inc. ranks 3rd of 20 Drug Manufacturers General companies by shares outstanding.

Shares outstanding, annual

Embed this chart

Annual newest first

Period Shares outstanding Change
FY2025 $2.5B (1.34%)
FY2024 $2.5B (0.24%)
FY2023 $2.5B 0.20%
FY2022 $2.5B 0.16%
FY2021 $2.5B (0.12%)
FY2020 $2.5B (1.51%)
FY2019 $2.6B (3.70%)
FY2018 $2.7B (2.51%)
FY2017 $2.7B (1.40%)
FY2016 $2.8B (1.90%)

Quarterly newest first

Period Shares outstanding Change
Jun 2026 $2.5B (0.08%)
Mar 2026 $2.5B (1.40%)
Dec 2025 $2.5B 0.36%
Sep 2025 $2.5B (0.60%)
42 more quarters

Against its own ten years

Low $2.5B High $2.8B
Ten-year median $2.5B
Current reading's percentile 9

Shares outstanding against peers

Company Shares outstanding
PFE Pfizer Inc. compare $5.7B
NVO Novo Nordisk A/S compare $4.4B
MRK Merck & Co., Inc. $2.5B
JNJ Johnson & Johnson compare $2.4B
NVS Novartis AG compare $1.9B
ABBV AbbVie Inc. compare $1.8B
AZN AstraZeneca PLC compare $1.6B
GILD Gilead Sciences, Inc. compare $1.2B
AMGN Amgen Inc. compare $544.0M

What Shares outstanding is

Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.

Reported line item

The full definition of Shares outstanding →

More on MRK